These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35596825)

  • 21. Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients.
    Schwartz MD; Peshkin BN; Isaacs C; Willey S; Valdimarsdottir HB; Nusbaum R; Hooker G; O'Neill S; Jandorf L; Kelly SP; Heinzmann J; Zidell A; Khoury K
    Breast Cancer Res Treat; 2018 Aug; 170(3):517-524. PubMed ID: 29611029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions.
    Murray ML; Cerrato F; Bennett RL; Jarvik GP
    Genet Med; 2011 Dec; 13(12):998-1005. PubMed ID: 21811163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
    Theobald KA; Susswein LR; Marshall ML; Roberts ME; Mester JL; Speyer D; Williams RNW; Knapke SC; Solomon SR; Murphy PD; Klein RT; Hruska KS; Solomon BD
    Ann Surg Oncol; 2018 Nov; 25(12):3556-3562. PubMed ID: 30167906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feasibility study of contralateral risk-reducing mastectomy with breast reconstruction for breast cancer patients with BRCA mutations in Japan.
    Yoshimura A; Okumura S; Sawaki M; Hattori M; Ishiguro J; Adachi Y; Kotani H; Gondo N; Kataoka A; Iwase M; Onishi S; Sugino K; Terada M; Horisawa N; Mori M; Takaiso N; Hyodo I; Iwata H
    Breast Cancer; 2018 Sep; 25(5):539-546. PubMed ID: 29520501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of retesting in patients with previously uninformative cancer genetics evaluations.
    Dettwyler SA; Koeppe ES; Jacobs MF; Stoffel EM
    Fam Cancer; 2022 Jul; 21(3):375-385. PubMed ID: 34545504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.
    Graves KD; Peshkin BN; Halbert CH; DeMarco TA; Isaacs C; Schwartz MD
    Breast Cancer Res Treat; 2007 Sep; 104(3):321-9. PubMed ID: 17066320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive Italian women.
    Cortesi L; Razzaboni E; Toss A; De Matteis E; Marchi I; Medici V; Tazzioli G; Andreotti A; De Santis G; Pignatti M; Federico M
    Ann Oncol; 2014 Jan; 25(1):57-63. PubMed ID: 24276029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing.
    Kwong A; Chu AT
    Asian Pac J Cancer Prev; 2012; 13(5):2241-7. PubMed ID: 22901201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association between age at breast cancer diagnosis and prevalence of pathogenic variants.
    Daly MB; Rosenthal E; Cummings S; Bernhisel R; Kidd J; Hughes E; Gutin A; Meek S; Slavin TP; Kurian AW
    Breast Cancer Res Treat; 2023 Jun; 199(3):617-626. PubMed ID: 37084156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study.
    Wevers MR; Schmidt MK; Engelhardt EG; Verhoef S; Hooning MJ; Kriege M; Seynaeve C; Collée M; van Asperen CJ; Tollenaar RA; Koppert LB; Witkamp AJ; Rutgers EJ; Aaronson NK; Rookus MA; Ausems MG
    Fam Cancer; 2015 Sep; 14(3):355-63. PubMed ID: 25700605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients.
    Woo J; Gwak G; Park I; Bae BN; Lee SK; Chae BJ; Yu J; Lee JE; Kim SW; Nam SJ; Ryu JM
    Sci Rep; 2021 Jul; 11(1):14747. PubMed ID: 34285295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients.
    Isiklar AD; Aliyeva L; Yesilyurt A; Soyder A; Basaran G
    Breast Cancer Res Treat; 2023 Nov; 202(2):297-304. PubMed ID: 37615792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of genetic counseling on the uptake of contralateral prophylactic mastectomy among younger women with breast cancer.
    Terkelsen T; Rønning H; Skytte AB
    Acta Oncol; 2020 Jan; 59(1):60-65. PubMed ID: 31379231
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy.
    Scott CI; Iorgulescu DG; Thorne HJ; Henderson MA; Phillips KA;
    Clin Genet; 2003 Aug; 64(2):111-21. PubMed ID: 12859406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients.
    Tynan M; Peshkin BN; Isaacs C; Willey S; Valdimarsdottir HB; Nusbaum R; Hooker G; O'Neill SC; Jandorf L; Kelly SP; Heinzmann J; Kelleher S; Poggi E; Schwartz MD
    Breast Cancer Res Treat; 2020 Feb; 180(1):177-185. PubMed ID: 31894446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
    Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L
    Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integration of Universal Germline Genetic Testing for All New Breast Cancer Patients.
    Culver JO; Freiberg Y; Ricker C; Comeaux JG; Chang EY; Banerjee V; Sturgeon D; Solomon I; Kagey J; Dobre MG; Carey J; Carr A; Cho S; Lu J; Kang IM; Patel K; Terando A; Ye JC; Li M; Lerman C; Spicer D; Nelson M
    Ann Surg Oncol; 2023 Feb; 30(2):1017-1025. PubMed ID: 36161375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.